J B Chemicals interim dividend: ₹12.70 for FY2026

Company and sector snapshot

J. B. Chemicals & Pharmaceuticals Limited operates in the Healthcare sector under Pharmaceuticals & Drugs. The company manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and international markets. The stock is listed on NSE as JBCHEPHARM and on BSE as 506943. Alongside earnings and product performance, dividends remain a closely tracked data point for the company. Market dashboards in the provided data also show valuation and yield metrics such as PB ratio and dividend yield.

What the board approved on February 5, 2026

The company said its board meeting held on February 5, 2026 approved an interim dividend of ₹12.70 per equity share. The dividend is on shares with a face value of ₹1, and the announcement describes it as 1270%. As per the corporate update, the payment is expected to be credited to shareholders on or after February 25, 2026. Another corporate actions line item also lists the dividend with an ex-date of February 11, 2026. The same February 5 board meeting also included a management update that the company appointed Kaushal Solanki as Chief Financial Officer and Key Managerial Personnel, effective February 5, 2026.

Dividend yield and payout ratio mentioned in the data

The provided data shows multiple dividend-yield readings across different snapshots. One section lists Dividend Yield: 0.70%, while another table shows Div Yield(%): 0.81, and a separate block shows 0.9% current dividend yield. The dataset also mentions a 41% payout ratio. A separate dividend note states there have been no dividend cuts, and that the company has increased or maintained dividend levels over the last five years. Another line estimates that an investment of ₹1,000 is expected to generate about ₹6.99 in annual dividend based on the stated yield.

Share price points referenced across dates

Several price points appear in the material, reflecting different dates and data sources. One line lists a current share price of ₹2,151.90, while another states the share price of JBCHEPHARM was ₹2,149.80 as on 8 May 2026. For an earlier reference, it says the stock last traded at ₹1,901.60 on 22 Jan, 2026, up 0.91% from the previous close of ₹1,884.60. Another market snapshot lists the share price at ₹1,708 with day levels (open, high, low) and 52-week range. Separately, a dividend page reference shows ₹2,076.8 (-0.17%) with a timestamp of Mar 24, 2026.

Key dividend timeline and past payouts

The company has declared 36 dividends since June 30, 2003, according to the provided dividend history line. Over the past 12 months in that dataset, it declared an equity dividend totaling ₹22.25 per share. The same section notes that at a share price of ₹1,689.40, the dividend yield worked out to 1.32%. Corporate actions listed in the material include final and interim dividends over multiple years, along with a face value split in 2023.

Financial performance references included in the data

The material includes operating and profit metrics from multiple periods. One note says the company delivered 11% revenue growth to ₹1,065 crore in the third quarter, citing a favorable product mix and cost management. It also says domestic market growth showed signs of slowing, particularly in the acute gastro portfolio, while the chronic segment remained strong. Another performance highlight states Q3 net profit rose 21.6% to ₹162.5 crore, and EBITDA increased 14.1% to ₹254.5 crore from ₹223.1 crore in the same quarter last year. Separately, it states that Q4 FY2024-25 net profit was ₹145.69 crore, up 15.48% year-on-year, while quarterly net profit fell 10.34%.

Table: Key facts cited in the provided dataset

Table: Quarterly financials shown (converted to ₹ crore)

Financial results were presented as “Amount in Lakhs” for the two quarters below. These have been converted to ₹ crore for consistency.

Market impact

The interim dividend amount and ex-date are typically watched by income-focused investors because they influence near-term shareholder cash flows. In the provided data, dividend yield readings vary by snapshot, with figures such as 0.70% and 0.81% appearing alongside different share prices. The board’s confirmation that the dividend will be credited on or after February 25, 2026 gives a clear payout window for eligible shareholders. Separately, the appointment of a new CFO effective the same day as the dividend approval is a material corporate update that can matter for disclosure quality and financial stewardship. The earnings expectation dated 11/05/2026 is another near-term marker, as dividend decisions are often analysed alongside profit trends and cash generation.

Analysis: What the dividend signals alongside results

A ₹12.70 interim dividend on a ₹1 face value share indicates a meaningful interim payout in absolute rupees per share, as stated in the announcement. The company’s payout ratio of 41% (as provided) offers one lens to compare dividends with profitability, although the article data does not provide a complete cash flow bridge. Recent results highlights in the dataset show growth in Q3 profit and EBITDA, while another reference points to a sequential profit decline in a later quarter. Those mixed signals are common in pharmaceuticals where product mix, costs, and domestic portfolio performance can shift quarter to quarter. Investors tracking J B Chemicals often combine dividend actions with profitability metrics such as margins and quarterly income, particularly ahead of scheduled earnings.

Conclusion

J. B. Chemicals & Pharmaceuticals has approved an interim dividend of ₹12.70 per share for FY2025-26, with an ex-date of February 11, 2026 and payment to shareholders on or after February 25, 2026. The same board meeting also marked the appointment of Kaushal Solanki as CFO effective February 5, 2026. With earnings flagged as expected on 11/05/2026, the next update investors will watch is the company’s results and any commentary that adds context to demand trends and margins.